Forum

Post edited 7:54 pm – December 14, 2009 by FM2020

I think Longevinex is sold in Europe, as is Biotivia.

The biochemist navigator on the resveratrol form at ImmInst, niner, accused a poster at ImmInst, (whose post was deleted), of promoting Biotivia. Since the post was deleted, one can't really know. But a European called niner out on what he called Biotivia bashing:

====

Hya niner,
mostly, your postings here contain useful things and information. However, I have to wonder a bit about the Biotivia-bashing. Inter alia you wrote:

"Even without consideration of the quality of their products, these practices are enough to keep me away from the company, because I simply can not trust them."

IMHO, this was a comment, which does not met the quality standards this forum should aim for…..

Did somebody from Biotivia pinch your girlfriend? Sorry, but the issue you obviously have with them looks a bit like a private vendetta….

=====

There is some good info at ImmInst, but misleading posts by the navigator maxwatt, at times…  (I still think Longevinex, RevGenetics, Biotivia and Vivix are quality products based on what I've read. There are others as well)

Post edited 2:19 pm – December 11, 2009 by RevGenetics

Thanks Dr. B,

The link for http://e-patients.net/ is intriguing. I will be looking it over this weekend.

thanks again,

Anthony Loera

RevGenetics

Drb2 said:

I used to work for a large pharma company and my participation in this meeting reminded me how conservative the industry is. When one talks about patient engagement and empowerment via social networking, the subject elicits a blank stare. It's not that the phenomenon is discounted — it is that the concept is totally foreign to them and one might as well be speaking a language from another planet. As far as most of the participants are concerned, there's only one way to discover and develop new medicines and this process requires 10-15 years and $800 million to $1.5 billion USD. The type of innovation they want is to extend the patent life of their compounds to justify this level of investment.

I'm not sharing these observations to start a flame-throwing contest against the industry, but to get your insights and opinions on how a forum like ours could advance new "out of the box" approaches.

Dr. B,

from what I read…

Patient Engagement: I believe this is a great method to begin building a relationship with the patient/customer. IF done in a public forum, it also provides answers for those who may not be inclined to post initially.

Extend Patent Life: This one is understandable for the sake of profits and stockholders. However this would require a conserted push by the European pharmas, and since it appears that the meeting achieved some sort of mental concensous on it (since other ideas were looked down upon), it leads me to believe that this maybe attempted by changing current laws.

Conservative Industry: Although not as easy to convert a conservative industry, it maybe possible only after a smaller pharma makes strides and profits tremendously from the way it does business. I have some ideas regarding this, however at this time, it would not be prudent for me to provide these ideas as I have projects in the works that will benefit from them.

I do like your updates, and I believe this is the conversation I find most interesting on this forum. Please keep it up.

thanks

Anthony Loera

RevGenetics